The progression of comorbidity in IL-18 transgenic chronic obstructive pulmonary disease mice model

Biochemical and Biophysical Research Communications

Volumn 445, Issue 3, 2014, Pages 597-601

  Takenaka, Shin ichi ^a   Kawayama, Tomotaka ^a   Imaoka, Haruki ^a   Sakazaki, Yuki ^a   Oda, Hanako ^a   Kaku, Yoichiro ^a   Matsuoka, Masanobu ^a   Okamoto, Masaki ^a   Kato, Seiya ^b   Yamada, Kentaro ^a   Hoshino, Tomoaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

COPD; IL 13; IL 18; Transgenic mouse

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 18; SURFACTANT PROTEIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HEART RIGHT VENTRICLE; IMPAIRED GLUCOSE TOLERANCE; MOUSE; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PULMONARY HYPERTENSION; WEIGHT REDUCTION; WILD TYPE;

MUS; MUS MUSCULUS;

COPD; IL-13; IL-18; TRANSGENIC MOUSE;

AGING; ANIMALS; BONE AND BONES; BONE DENSITY; COMORBIDITY; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INTERLEUKIN-13; INTERLEUKIN-18; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLES; ORGAN SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; WEIGHT LOSS;

EID: 84896316970     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.02.052     Document Type: Article

References (45)

1. Peto R., Chen Z.M., Boreham J. Tobacco - the growing epidemic. Nat. Med. 1999, 5:15-17.
2. Pauwels R.A., Rabe K.F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364:613-620.
3. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009, 33:1165-1185.
4. Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000, 343:269-280.
5. Garlanda C., Dinarello C.A., Mantovani A. The interleukin-1 family: back to the future. Immunity 2013, 39:1003-1018.
6. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 2001, 19:423-474.
7. Hoshino T., Wiltrout R.H., Young H.A. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. 1999, 162:5070-5077.
8. Hoshino T., Yagita H., Ortaldo J.R., Wiltrout R.H., Young H.A. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur. J. Immunol. 2000, 30:1998-2006.
9. Hoshino T., Kawase Y., Okamoto M., Yokota K., Yoshino K., Yamamura K., Miyazaki J., Young H.A., Oizumi K. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J. Immunol. 2001, 166:7014-7018.
10. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
11. Kawase Y., Hoshino T., Yokota K., Kuzuhara A., Kirii Y., Nishiwaki E., Maeda Y., Takeda J., Okamoto M., Kato S., Imaizumi T., Aizawa H., Yoshino K. Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with targeted interleukin-18 expression in the skin. J. Invest. Dermatol. 2003, 121:502-509.
12. Okamoto M., Kato S., Oizumi K., Kinoshita M., Inoue Y., Hoshino K., Akira S., McKenzie A.N., Young H.A., Hoshino T. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 2002, 99:1289-1298.
13. Hoshino T., Okamoto M., Sakazaki Y., Kato S., Young H.A., Aizawa H. Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am. J. Respir. Cell Mol. Biol. 2009, 41:661-670.
14. Kitasato Y., Hoshino T., Okamoto M., Kato S., Koda Y., Nagata N., Kinoshita M., Koga H., Yoon D.Y., Asao H., Ohmoto H., Koga T., Rikimaru T., Aizawa H. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2004, 31:619-625.
15. Imaoka H., Hoshino T., Takei S., Kinoshita T., Okamoto M., Kawayama T., Kato S., Iwasaki H., Watanabe K., Aizawa H. Interleukin-18 production and pulmonary function in COPD. Eur. Respir. J. 2008, 31:287-297.
16. Kang M.J., Homer R.J., Gallo A., Lee C.G., Crothers K.A., Cho S.J., Rochester C., Cain H., Chupp G., Yoon H.J., Elias J.A. IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation. J. Immunol. 2007, 178:1948-1959.
17. Singh D., Fox S.M., Tal-Singer R., Plumb J., Bates S., Broad P., Riley J.H., Celli B., Investigators E. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax 2011, 66:489-495.
18. Hoshino T., Kato S., Oka N., Imaoka H., Kinoshita T., Takei S., Kitasato Y., Kawayama T., Imaizumi T., Yamada K., Young H.A., Aizawa H. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am. J. Respir. Crit. Care Med. 2007, 176:49-62.
19. Suzuki A., Hanada T., Mitsuyama K., Yoshida T., Kamizono S., Hoshino T., Kubo M., Yamashita A., Okabe M., Takeda K., Akira S., Matsumoto S., Toyonaga A., Sata M., Yoshimura A. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 2001, 193:471-481.
20. Ichiki H., Hoshino T., Kinoshita T., Imaoka H., Kato S., Inoue H., Nakamura H., Yodoi J., Young H.A., Aizawa H. Thioredoxin suppresses airway hyperresponsiveness and airway inflammation in asthma. Biochem. Biophys. Res. Commun. 2005, 334:1141-1148.
21. Imaoka H., Hoshino T., Takei S., Sakazaki Y., Kinoshita T., Okamoto M., Kawayama T., Yodoi J., Kato S., Iwanaga T., Aizawa H. Effects of thioredoxin on established airway remodeling in a chronic antigen exposure asthma model. Biochem. Biophys. Res. Commun. 2007, 360:525-530.
22. Miyamoto K., Yoshida S., Kawasumi M., Hashimoto K., Kimura T., Sato Y., Kobayashi T., Miyauchi Y., Hoshi H., Iwasaki R., Miyamoto H., Hao W., Morioka H., Chiba K., Kobayashi T., Yasuda H., Penninger J.M., Toyama Y., Suda T., Miyamoto T. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J. Exp. Med. 2011, 208:2175-2181.
23. Yamada K., Nonaka K., Hanafusa T., Miyazaki A., Toyoshima H., Tarui S. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. An observation in nonobese diabetic (NOD) mice. Diabetes 1982, 31:749-753.
24. Agusti A.G., Noguera A., Sauleda J., Sala E., Pons J., Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003, 21:347-360.
25. Di Francia M., Barbier D., Mege J.L., Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1994, 150:1453-1455.
26. de Godoy I., Donahoe M., Calhoun W.J., Mancino J., Rogers R.M. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am. J. Respir. Crit. Care Med. 1996, 153:633-637.
27. Eid A.A., Ionescu A.A., Nixon L.S., Lewis-Jenkins V., Matthews S.B., Griffiths T.L., Shale D.J. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001, 164:1414-1418.
28. Schols A.M. Pulmonary cachexia. Int. J. Cardiol. 2002, 85:101-110.
29. Ionescu A.A., Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur. Respir. J. Suppl. 2003, 46:64s-75s.
30. Ohara T., Hirai T., Muro S., Haruna A., Terada K., Kinose D., Marumo S., Ogawa E., Hoshino Y., Niimi A., Chin K., Mishima M. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008, 134:1244-1249.
31. Graat-Verboom L., Wouters E.F., Smeenk F.W., van den Borne B.E., Lunde R., Spruit M.A. Current status of research on osteoporosis in COPD: a systematic review. Eur. Respir. J. 2009, 34:209-218.
32. Friedman G.D., Klatsky A.L., Siegelaub A.B. Lung function and risk of myocardial infarction and sudden cardiac death. N. Engl. J. Med. 1976, 294:1071-1075.
33. Hole D.J., Watt G.C., Davey-Smith G., Hart C.L., Gillis C.R., Hawthorne V.M. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996, 313:711-715. (discussion 715-716).
34. Schunemann H.J., Dorn J., Grant B.J., Winkelstein W., Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000, 118:656-664.
35. Marquis K., Maltais F., Duguay V., Bezeau A.M., LeBlanc P., Jobin J., Poirier P. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J. Cardiopulm. Rehabil. 2005, 25:226-232. (discussion 233-224).
36. Mannino D.M., Thorn D., Swensen A., Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 2008, 32:962-969.
37. Ito K., Kawayama T., Shoji Y., Fukushima N., Matsunaga K., Edakuni N., Uchimura N., Hoshino T. Depression, but not sleep disorder, is an independent factor affecting exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. Respirology 2012, 17:940-949.
38. Sekiduka-Kumano T., Kawayama T., Ito K., Shoji Y., Matsunaga K., Okamoto M., Edakuni N., Imaoka H., Uchimura N., Hoshino T. Positive association between the plasma levels of 5-hydroxyindoleacetic acid and the severity of depression in patients with chronic obstructive pulmonary disease. BMC Psychiatry 2013, 13:159.
39. Udagawa N., Horwood N.J., Elliott J., Mackay A., Owens J., Okamura H., Kurimoto M., Chambers T.J., Martin T.J., Gillespie M.T. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J. Exp. Med. 1997, 185:1005-1012.
40. Yamada N., Niwa S., Tsujimura T., Iwasaki T., Sugihara A., Futani H., Hayashi S., Okamura H., Akedo H., Terada N. Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone 2002, 30:901-908.
41. Petersen A.M., Penkowa M., Iversen M., Frydelund-Larsen L., Andersen J.L., Mortensen J., Lange P., Pedersen B.K. Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung 2007, 185:161-171.
42. Agusti A.G., Sauleda J., Miralles C., Gomez C., Togores B., Sala E., Batle S., Busquets X. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002, 166:485-489.
43. Hashimoto W., Osaki T., Okamura H., Robbins P.D., Kurimoto M., Nagata S., Lotze M.T., Tahara H. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J. Immunol. 1999, 163:583-589.
44. Nagai N., Ito Y., Okamoto N., Shimomura Y., Okamura H. Changes in interleukin 18 in the retinas of Otsuka long-evans Tokushima fatty rats, a model of human type 2 diabetes. J. Oleo Sci. 2013, 62:513-523.
45. Dinarello C.A., Novick D., Kim S., Kaplanski G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 2013, 4:289.